Autoimmune polyendocrine syndrome type 1 (APS-1) is a life-threatening, autosomal recessive syndrome caused by autoimmune ...

Approved on-demand treatments for hereditary angioedema attacks need to be administered parenterally, a route of ...

We conducted a phase 2 study in which patients with nonmetastatic, locally advanced, previously untreated dMMR colon cancer were treated with neoadjuvant nivolumab plus ipilimumab. The two primary ...

Magnesium is an important cofactor for numerous enzymes. All ATPase reactions require Mg 2+ –ATP, including those involved in RNA and DNA biologic functions. It opposes calcium actions and acts ...

Genetic variants that cause rare disorders may remain elusive even after expansive testing, such as exome sequencing. The diagnostic yield of genome sequencing, particularly after a negative ...

Hereditary angioedema is a rare disorder characterized by recurrent episodes of mucosal swelling. The disease is usually ...

Hepatitis D virus (HDV) infection is the most serious form of viral hepatitis, with an accelerated clinical course and heightened risks of cirrhosis and liver cancer. 1 No therapies for HDV ...

Dr. Kevin S. Oh (Radiation Oncology): A 45-year-old woman was evaluated in the oncology clinic of this hospital because of metastatic triple-negative breast cancer. The patient had been well until ...

Bortezomib, lenalidomide, and dexamethasone (VRd) is a preferred first-line treatment option for patients with newly diagnosed multiple myeloma. Whether the addition of the anti-CD38 monoclonal ...

Many of the challenges we address here were evident to the pioneers of medical decision analysis of the 1950s 7 and to scholars in subsequent decades 8-11 who conducted careful and creative ...

In phase 1–2 trials in patients with resectable, macroscopic stage III melanoma, neoadjuvant immunotherapy was more efficacious than adjuvant immunotherapy. In this phase 3 trial, we randomly ...

A total of 216 patients who had undergone chemoradiotherapy were randomly assigned to receive osimertinib (143 patients) or placebo (73 patients). Osimertinib resulted in a significant progression ...